智通财经APP讯，派格生物医药-B(02565)发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元(人民币，下同);研发开支5038.7万元;每股基本亏损0.55元。
截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。
截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗，通过持续创新，内部评估显示多款候选药物兼具“同类首创”(FIC)与“同类最优”(BIC)的双重价值潜力，为未来市场竞争力奠定坚实基础。
随着核心产品派达康®(PB-119)于2025年11月成功获得上市批准，集团将全面推进其在中国市场的商业化落地工作。未来，集团将围绕产品上市后的市场准入推进、商业化运营体系完善及患者可及性提升等方面持续开展相关工作，以支持产品上市后的市场渗透及临床使用场景拓展，并逐步推动产品价值的释放。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.